Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: J Clin Pharmacol. 2018 May 18;58(9):1184–1195. doi: 10.1002/jcph.1118

Table 2.

Estimated population pharmacokinetic parameters of tacrolimus and bootstrap validation

Population modeling Bootstrap (n=1000)
Parameter - Symbol Estimates RSE (%) Median 95% CI Biasa (%)
CL/F (L.hr−1) − θCL/F 19.7 6.30 19.6 17.5 – 22.1 −0.10
CYP3A5*3*6*7 on CL/F
CIMCYP3A5θ2 1.45 9.90 1.46 1.20 – 1.78 0.01
CEMCYP3A5θ3 2.25 13.6 2.28 1.64 – 3.01 0.03
V/F (L) − θV/F 234 10.2 231 190 – 276 −3.00
CLp/F (L.hr−1) − θCLp/F 52.6 9.50 53.2 44.1 – 63.6 0.60
Vp/F (L) − θVp/F 403 20.1 404 275 – 572 1.00
ka (hr−1) − θka 4.21 20.3 4.14 2.77 – 5.74 −0.07
Lag time (hr) − θlag 0.828 3.80 0.830 0.740 – 0.873 0.002
Between-subject variability
BSV CL/F (CV%) − η1 37.0 6.20 36.1 30.9 – 40.7 −0.9
BSV V/F (CV%) − η2 76.7 12.1 76.0 56.0 – 93.5 −0.7
BSV CLp/F (CV%) − η3 48.6 16.5 47.8 29.4 – 64.9 −0.8
BSV ka (CV%) − η4 69.4 16.5 68.6 48.3 – 93.9 −0.8
Residual variability
Proportional error − ε1 9.00 5.60 8.90 8.04 – 9.83 −0.1

RSE (%) Percent relative standard error of the estimate; 95% CI 95th Confidence interval: 2.5 and 97.5th percentiles, BSV Between-subject variability expressed as percent coefficient of variation (CV%); CL/F =Apparent elimination clearance; CLp/F Apparent distribution clearance; V/F Apparent central volume of distribution; Vp/F Apparent peripheral volume of distribution; ka Absorption rate.

a

The bias of each parameter was calculated by computing the difference between the median value derived from the bootstrap and the final parameter estimate.

99% of the bootstraps runs minimized successfully (990/1000).

Final pharmacokinetic model (typical individual values):

CL/Fi=θCL/F×θ2H1×θ3H2 and V/Fi=θV1/F×(TBW85.9)

where H1 = 1 for CYP3A5 intermediate metabolizers (cIMCYP3A5) and H2 = 1 for CYP3A5 extensive metabolizers (cEMCYP3A5). TBW Total body weight (kg)